Candel reports prostate cancer drug's long-term data ahead of FDA filing

Paul Peter Tak, Candel Therapeutics CEO (via Citryll) May 15, 2026 11:30 AM EDT R&D Can­del re­ports prostate can­cer drug's long-term da­ta ahead of FDA fil­ing Nicole DeFeudis Senior Reporter Can­del Ther­a­peu­tics pro­duced long-term fol­low-up da­ta that may bol­ster the case for its prostate can­cer drug that’s head­ing to the FDA for mar­ket­ing ap­proval lat­er … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER